| 1 |
32274564 | Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer. | 2020 May |
1 |
| 2 |
27108243 | Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. | 2016 Jun |
1 |
| 3 |
27165728 | Colorectal Cancer Yields to Dual HER2 Blockade. | 2016 Jul |
1 |
| 4 |
22458846 | Therapeutic efficiency of everolimus and lapatinib in xenograft model of human colorectal carcinoma with KRAS mutation. | 2013 Aug |
1 |
| 5 |
23076814 | EGFR and HER2 inhibition in pancreatic cancer. | 2013 Jun |
1 |
| 6 |
21271222 | KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib. | 2011 Apr |
2 |
| 7 |
20103665 | Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status. | 2010 Feb 1 |
2 |